基于体重指数的腹股沟下旁路术与血管内治疗的死亡率和截肢结局比较
研究基于血管质量倡议数据库2012至2023年118622例跛行或慢性肢体威胁性缺血患者,按体重指数分五组比较腹股沟下旁路术与血管内治疗。旁路术在正常体重和肥胖患者中30天死亡率更低,在除病态肥胖外各体重指数组1年死亡率更低,正常体重者1年截肢风险更低。
要点
- 正常体重患者旁路术较血管内治疗30天死亡率更低(aOR 0.45,95%CI 0.33-0.62)。
- 除病态肥胖外,旁路术在所有体重指数组与更低1年死亡率相关。
- 正常体重患者旁路术1年截肢风险更低(aOR 0.82,95%CI 0.70-0.96)。
核心结论
- 腹股沟下旁路术与血管内治疗在30天和1年死亡率、截肢及截肢/死亡率的差异随体重指数组不同而变化。
- 旁路术在正常体重和肥胖患者以及大多数体重指数组的慢性肢体威胁性缺血患者中与更好结局相关。
- 作者认为该发现提示腹股沟下旁路术较血管内治疗有长期生存获益,该效应被症状严重程度放大,但手术风险本身较高的患者除外。
研究设计与样本
- 回顾性队列研究,查询血管质量倡议数据库2012至2023年因跛行或慢性肢体威胁性缺血接受血管内治疗或使用大隐静脉的腹股沟下旁路术的患者。
- 共纳入118622例患者,按体重指数分为五组:体重不足(BMI≤18.5 kg/m2)3542例(3%)、正常体重(BMI 18.5-24.9 kg/m2)33009例(28%)、超重(BMI 25.0-29.9 kg/m2)40582例(34%)、肥胖(BMI 30.0-39.9 kg/m2)36494例(31%)、病态肥胖(BMI 40.0-49.9 kg/m2)4995例(4%)。
- 采用多变量logistic回归比较各体重指数组内旁路术与血管内治疗的30天死亡率,采用Cox回归、Kaplan-Meier生存分析和log-rank检验评估1年死亡率、1年截肢率和1年截肢/死亡率,并按适应证(慢性肢体威胁性缺血或跛行)进行亚组分析。
主要发现
- 体重不足患者中旁路术与血管内治疗的30天死亡率无显著差异。
- 正常体重患者旁路术与更低30天死亡率相关(aOR 0.45,95%CI 0.33-0.62),肥胖患者旁路术与更低30天死亡率相关(aOR 0.78,95%CI 0.24-0.75,原文如此)。
- 除病态肥胖患者外,旁路术在所有体重指数组均与更低1年死亡率相关。
- 正常体重患者旁路术与更低1年截肢风险相关(aOR 0.82,95%CI 0.70-0.96),正常体重、超重和肥胖患者旁路术与更低1年截肢/死亡风险相关。
- 慢性肢体威胁性缺血患者中,除体重不足者外,旁路术在所有体重指数组均与更低30天和1年死亡风险相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Obese patients have higher rates of cardiovascular disease and associated risk factors, but lower rates of peripheral artery disease and better outcomes after revascularization. This results in an obesity paradox, where obese patients have the lowest risk of adverse outcomes following treatment, while underweight and morbidly obese patients are at the highest risk. No previous studies have compared outcomes of endovascular vs open bypass within each body mass index (BMI) group. Our study aims to compare outcomes of peripheral vascular intervention (PVI) with infrainguinal bypass (IIB) stratified by patient BMI group. METHODS: The Vascular Quality Initiative database was queried for patients presenting with claudication or chronic limb-threatening ischemia (CLTI) undergoing PVI or IIB (using the great saphenous vein) from 2012 to 2023. Patients were categorized into five BMI groups: underweight (BMI ≤ 18.5 kg/m2), normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25.0-29.9 kg/m2), obese (BMI 30.0-39.9 kg/m2), and morbidly obese (BMI 40.0-49.9 kg/m2). Multivariable logistic compared 30-day mortality for IIB vs PVI within each BMI group. Cox regression, Kaplan-Meier survival analysis, and log-rank tests assessed 1-year mortality, 1-year amputation, and 1-year amputation/death rates. Subgroup analysis was performed by indication (CLTI or claudication). RESULTS: There were 118,622 patients meeting the study criteria, including 3542 underweight (3%), 33,009 normal weight (28%), 40,582 overweight (34%), 36,494 obese (31%), and 4995 morbidly obese (4%) patients. There was no significant difference in 30-day mortality between PVI and IIB in underweight patients. IIB was associated with lower 30-day mortality in normal weight (adjusted odds ratio [aOR], 0.45; 95% confidence interval [CI], 0.33-0.62) and obese (aOR, 0.78; 95% CI, 0.24-0.75) patients. Bypass was associated with lower 1-year mortality in all BMI groups, except for morbidly obese patients. It was also associated with a lower risk of 1-year amputation for normal weight (aOR, 0.82; 95% CI, 0.70-0.96) and a lower risk of 1-year amputation/death for normal weight, overweight, and obese patients. Among CLTI patients, bypass was associated with decreased 30-day and 1-year mortality risks in all but underweight patients. CONCLUSIONS: This study shows significant differences in 30-day and 1-year mortality, amputation, and amputation/death rates between PVI and IIB based on BMI depending on patient BMI. Bypass was associated with better outcomes for normal weight and obese patients, and for CLTI patients across most BMI groups. This finding suggests a long-term survival benefit after IIB compared with PVI, an effect potentiated by symptom severity, except for patients otherwise at a higher operative risk regardless of procedure choice.
引用
- Kricfalusi M, Hamouda M, Abdelkarim A, et al. Mortality and amputation outcomes of infrainguinal bypass versus endovascular therapy based on body mass index. J Vasc Surg. 2025. PMID: 39984140. doi:10.1016/j.jvs.2025.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。